Candel Therapeutics, Inc.
CADL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.15 | -0.00 | 0.20 | -0.91 |
| FCF Yield | -9.83% | -81.58% | -63.41% | -10.72% |
| EV / EBITDA | -3.57 | -0.80 | -0.25 | -5.83 |
| Quality | ||||
| ROIC | -41.52% | -105.40% | -47.56% | -30.68% |
| Gross Margin | 0.00% | 0.00% | -689.60% | -85.60% |
| Cash Conversion Ratio | 0.49 | 0.90 | 1.67 | 0.62 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | 0.00% | 0.00% |
| Free Cash Flow Growth | 22.08% | -6.07% | -36.02% | -128.06% |
| Safety | ||||
| Net Debt / EBITDA | 1.71 | 0.34 | 2.73 | 3.36 |
| Interest Coverage | -15.97 | -74.69 | -20.33 | -485.40 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -87.38 | -6.42 | -140.53 | -2,501.51 |